Online inquiry

IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7602MR)

This product GTTS-WQ7602MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF3R gene. The antibody can be applied in Neutropenia research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000760.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1441
UniProt ID Q99062
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7602MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ564MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ19MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 2130
GTTS-WQ13780MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ15433MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ13779MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ4920MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ3963MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ8722MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW